Nature: Systematic Review of Barriers to Implementing Deep Brain Stimulation in Psychiatry
Analysis of 28 studies identified key obstacles to using DBS for OCD and treatment-resistant depression: stigmatization, ethical controversies, and lack of physician knowledge. Educational initiatives and the creation of specialized centers are proposed to expand access.
An analysis of the situation regarding the implementation of DBS in psychiatry. This is not a summary of the review, but a look at the structural gap between proven efficacy and clinical inertia, which became apparent thanks to this publication.
The Core: What Is Really Happening
The publication in Translational Psychiatry (Nature Publishing Group) is not just an academic systematization of 28 studies. It is a moment of official acknowledgment of translational medicine's failure in psychiatry. The authors from Amsterdam UMC, led by Dominika Karaszewska and under the supervision of Damiaan Denys—one of the world leaders in DBS psychiatry—are essentially publicly admitting: we have created a technology that truly works for OCD and treatment-resistant depression, but patients are not receiving it.
The review's findings read like a diagnosis of the healthcare system itself: the number of referrals for DBS is significantly lower than expected based on prevalence and selection criteria. This is not a technological barrier. It is a barrier of perception, institutional inertia, and ethical cowardice. The article's main message is that DBS suffers not from a lack of evidence, but from its "media image," stigma, and knowledge gaps among clinicians.
As an analyst, what worries me most is the limitation honestly noted by the authors: a significant portion of the included articles come from the same researchers, and studies from the USA dominate. This means we are dealing not with a global consensus, but with an echo chamber of a few academic centers trying to sell their expertise to the rest of the world.
Timeline and Context
DBS for movement disorders (Parkinson's disease, essential tremor) is a routine procedure. Over 200,000 patients have been implanted worldwide. The DBS device market was valued at $1,468 million in 2025, with a projected growth to $2,925 million by 2032. Medtronic and Abbott control over 70% of new implantations. But all of this is neurology.
In psychiatry, the numbers are minuscule. Denys and his group in Amsterdam have published impressive results for years: up to 60% remission in OCD patients who had failed everything. However, the actual number of implantations for psychiatric indications in Europe is in the hundreds, not tens of thousands. The review by Karaszewska et al. appears now because a critical gap has accumulated between the evidence base and real-world practice.
Meanwhile, the neurointerface market is developing: the total market for implantable neurostimulation devices is already $6.8 billion in 2025, with a forecast of $21 billion by 2034. Psychiatric applications represent a new frontier that could double the market. But without addressing the barriers described in the review, this growth will remain on paper.
Who Wins and Who Loses
Winners are major device manufacturers—Medtronic, Abbott, Boston Scientific. For them, psychiatry is an untapped segment with potential for $450–600 million in additional annual revenue. Once barriers begin to crumble, their Percept PC and Infinity DBS systems with directional stimulation and sensing capabilities for neurobiomarkers will instantly capture the market. They are already funding educational initiatives for psychiatrists—exactly what the review recommends as a key implementation tool.
Winners are specialized centers. The review directly recommends creating "specialized psychiatric DBS services." This means concentrating resources in the hands of a few clinics that will become monopolists in this field.
Losers are general psychiatrists and small clinics. If the review recommends "educational initiatives" to overcome knowledge gaps, it means the authors consider the current level of psychiatrist training inadequate. A psychiatrist who does not understand the neuroanatomy of CSTC loops (cortico-striato-thalamo-cortical) cannot refer a patient for DBS. And such psychiatrists are the majority.
Losers are patients with treatment-resistant depression in countries with conservative regulation. Regulatory uncertainty is named a key barrier. Until the FDA and EMA give clear signals, insurers will not cover a procedure costing $80,000–120,000 per implantation, and patients will remain without access.
What the Media Leaves Out
Most headlines have focused on "barriers"—stigma, ethics, knowledge. But the review authors make a subtle and important move: they acknowledge that one of the main problems is the lack of consensus on the definition of treatment resistance. This is not just an academic quibble.
It means we do not know at what point a patient with depression "deserves" DBS. After three failed antidepressant courses? After five? After ECT? No one has agreed. And without this consensus, any psychiatrist can endlessly cycle through medications, postponing referral for neurosurgery for years.
Insider insight: I suspect that the Denys group is deliberately publishing this review now as a tool for political pressure. They need a formal document in a peer-reviewed journal from the Nature group to go to regulators and insurers in the EU and say: "Look, science says the problem is not our technology, but your system." This is a classic tactic of translational researchers—using a systematic review as leverage to change clinical guidelines.
Another underestimated point: the ethical debate around "personality change" after DBS. On psychiatrist forums and in philosophical works, there is active discussion about whether stimulation alters the patient's "self." This is not just philosophy—it directly affects a patient's willingness to give informed consent. The review calls this "ethical concerns," but no one says that this very discussion creates a paralyzing effect among clinicians: "Will I be sued for changing the patient's personality?"
Forecast: Next 30 Days and 90 Days
30 days (by June 18, 2026): The publication will trigger a wave of comments from professional associations—APA (American Psychiatric Association) and EPA (European Psychiatric Association). I expect at least one statement calling for "cautious optimism." Simultaneously, Medtronic and Abbott will ramp up their support programs for educational initiatives—exactly what the review calls "facilitators." Watch for news about grants for psychiatrist training from these companies.
90 days (by August 19, 2026): The key moment is the reaction from regulatory bodies. If the FDA issues draft recommendations for expanding DBS indications in psychiatry, the device market will immediately react with rising stock prices. More realistically, however, a working group will be formed to standardize the definition of "treatment resistance"—without this, any regulatory step is premature.
The most interesting developments will occur at the insurer level. If one of the major payers in the USA (e.g., UnitedHealthcare), influenced by this review, changes its coverage policy for DBS for OCD, it will trigger an avalanche of expanded access. For now, we are in limbo: the technology exists, the evidence exists, but no one wants to take responsibility for being first. This review is an attempt to create enough academic weight to move the system off dead center. Whether it succeeds, we will see by autumn.
— Editorial Team
